🟢 Strong Evidence
A 2024 Cochrane systematic review of 34 randomised controlled trials involving 8,526 participants found that zinc supplements offer limited protection against the common cold, while consistently causing side effects. The evidence for zinc’s most promoted benefit—shortening cold duration—is substantially weaker than the evidence documenting its harms, a distinction that has largely disappeared from supplement marketing.
Key takeaways
- Zinc provides no protection against catching a cold, according to pooled analysis of 34 RCTs
- Cold duration may be shortened by roughly 2 days, but extreme study variability (97% heterogeneity) undermines confidence in this finding
- A 34% increase in side effects (bad taste, nausea, gastrointestinal discomfort) is supported by moderate-to-high certainty evidence
- Symptom severity was unaffected by zinc in both prevention and treatment
Study at a Glance
| Source | Cochrane Database of Systematic Reviews |
| Study type | Systematic review and meta-analysis of 34 RCTs |
| Sample size | 8,526 participants across included trials |
| Population | General population; separate analyses for prevention and treatment |
| Country | Multi-national (included trials from multiple countries) |
Zinc Supplementation: Evidence Certainty by Outcome
Comparison of certainty ratings across four outcomes in the 2024 Cochrane review of 34 RCTs (8,526 participants)
Source: Nault et al., Cochrane Database Syst Rev, 2024 | Georgian Medical Journal News
No Protection Against Catching a Cold
The most straightforward finding from the Cochrane review by Nault and colleagues is also the most definitive: zinc supplementation does not reduce the risk of developing a cold in the first place. This was established with low certainty evidence, meaning the confidence in this null finding is moderate, yet the direction is clear across studies.
For patients and clinicians considering zinc as a preventive strategy during cold season, this finding undermines one of the supplement’s central marketing claims. The review’s authors found insufficient evidence of any protective benefit, making zinc difficult to recommend as a primary prevention tool. This has important implications for public health messaging, particularly in populations where supplement use is promoted as a cost-effective alternative to vaccination or basic hygiene measures. See Clinical Updates for related treatment guidance.
Possible Reduction in Cold Duration—With a Critical Caveat
Where zinc showed some potential was in shortening the duration of illness once a cold has already begun. The pooled estimate suggested that zinc treatment might reduce cold duration by approximately 2 days, according to the Cochrane analysis. However, this finding comes with a substantial methodological asterisk.
The heterogeneity across the 34 included trials was extreme, with an I² statistic of 97%—meaning that 97% of the observed variation in results reflected genuine differences between studies rather than random chance. Such high heterogeneity typically signals that the pooled estimate obscures rather than clarifies the true effect. Some trials found zinc reduced cold duration; others found no effect; still others suggested potential harm. The authors noted this inconsistency undermines confidence in the estimate, effectively downgrading the certainty of evidence to low. For patients considering zinc for an active cold, this means the benefit is plausible but unproven at scale.
Side Effects Are the Most Reliably Documented Outcome
In a striking inversion of typical supplement marketing, the most statistically robust finding in the entire review concerned adverse effects, not benefits. Zinc supplementation was associated with a 34% increase in non-serious side effects—predominantly bad taste, nausea, and gastrointestinal discomfort—with moderate certainty evidence supporting this estimate.
This distinction matters because it suggests that patients are more likely to experience documented harm than documented benefit. The certainty rating for side effects (moderate) exceeds that for the duration benefit (low), meaning clinicians have stronger evidence that a patient will suffer nausea or dysgeusia than that they will recover 2 days faster. The Nault review found no effect on symptom severity, regardless of whether zinc was used preventively or therapeutically, further limiting its clinical appeal. For further discussion of supplement safety, see Pharmacy & Prescribing coverage.
Implications for Clinical Practice and Patient Counselling
These findings reflect a broader challenge in supplement evidence: the gulf between marketing claims and published data. Zinc lozenges and tablets are widely sold over-the-counter with claims of cold prevention and symptom relief. The 2024 Cochrane review suggests both claims lack robust support, while side effects are well-documented. Clinicians counselling patients on cold management should acknowledge that zinc may shorten illness duration in some individuals, but the evidence is weak and highly inconsistent across studies, and that gastrointestinal complaints are a realistic expectation.
The 34% increase in non-serious side effects from zinc is supported by moderate certainty evidence, while the potential 2-day reduction in cold duration rests on low certainty evidence and 97% heterogeneity across studies.
— Nault et al., Cochrane Database of Systematic Reviews (2024)
What this means
Frequently asked questions
Does zinc prevent the common cold?
No. The 2024 Cochrane review found no evidence that zinc supplementation reduces the risk of catching a cold, according to pooled analysis of 34 RCTs with 8,526 participants. Marketing claims to this effect lack scientific support.
Can zinc shorten a cold once I have one?
Possibly, but the evidence is weak and inconsistent. The review found a potential reduction of about 2 days in cold duration, but heterogeneity across trials was so high (I² = 97%) that confidence in this estimate is low. Results varied widely between studies, undermining the pooled finding.
What side effects should I expect from zinc supplements?
Zinc carries a 34% increased risk of non-serious adverse effects, primarily bad taste, nausea, and gastrointestinal discomfort, according to the Cochrane analysis. This is the most reliably documented outcome in the review—supported by moderate certainty evidence.
The 2024 Cochrane review provides a sobering lesson in the gap between supplement marketing and evidence. As healthcare providers and patients increasingly turn to over-the-counter remedies for common illnesses, rigorous systematic reviews like this one offer essential reality-checking. Zinc’s case exemplifies how a supplement can be simultaneously plausible (shortening cold duration is theoretically coherent), popular (it is widely available and purchased), and poorly supported by evidence when the full picture—including side effects and study heterogeneity—is examined. Future trials should aim to resolve the sources of inconsistency and establish clearer patient subgroups, if any, who benefit from zinc therapy.
Source: Nault et al., Cochrane Database of Systematic Reviews, 2024
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
